Chronic experimental diabetes accelerates urinary elimination of deprenyl and its metabolites

Ernest Adeghate, P. Sótonyi, H. Kalász

Research output: Contribution to journalArticle

Abstract

Many diabetic patients take several medications to treat diabetes-associated complications and other ailments. The mode of elimination of these drugs and their metabolites are poorly understood. The elimination of deprenyl, a MAO-B inhibitor, used for the treatment of the early stage of Parkinson's disease and senile dementia was investigated using thin layer chromatography.Male Wistar rats (180-200 g) were rendered diabetic by streptozotocin (STZ) treatment (60 mg/kg, i.v.). Rats having at least three times higher plasma glucose level than the normal were considered diabetic. Rats were treated with a single oral dose of 5 mg/kg (14)C-(methyl)-labeled (-)-deprenyl, 98 microCi/mg. Diabetic rats excreted the majority of urinary radioactivity in 8 hours, while control rats did it in 16 hours. The approximate ratio of major metabolites as determined using thin-layer chromatography did not change. In conclusion, diabetic rats excreted radiolabelled-deprenyl more rapidly compared to control animals. Increased elimination of deprenyl should be taken into account in the management of patients suffering from diabetes.

Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalThe open medicinal chemistry journal
Volume2
DOIs
Publication statusPublished - Jan 10 2008

Fingerprint

Selegiline
Thin Layer Chromatography
Monoamine Oxidase Inhibitors
Monoamine Oxidase
Diabetes Complications
Streptozocin
Radioactivity
Parkinson Disease
Wistar Rats
Alzheimer Disease
Glucose
Therapeutics
Pharmaceutical Preparations

Keywords

  • Deprenyl
  • diabetes
  • pharmacokinetics
  • urinary elimination.

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Chronic experimental diabetes accelerates urinary elimination of deprenyl and its metabolites. / Adeghate, Ernest; Sótonyi, P.; Kalász, H.

In: The open medicinal chemistry journal, Vol. 2, 10.01.2008, p. 1-5.

Research output: Contribution to journalArticle

@article{ef9f79cf95e642e1988c11f6ac40e260,
title = "Chronic experimental diabetes accelerates urinary elimination of deprenyl and its metabolites",
abstract = "Many diabetic patients take several medications to treat diabetes-associated complications and other ailments. The mode of elimination of these drugs and their metabolites are poorly understood. The elimination of deprenyl, a MAO-B inhibitor, used for the treatment of the early stage of Parkinson's disease and senile dementia was investigated using thin layer chromatography.Male Wistar rats (180-200 g) were rendered diabetic by streptozotocin (STZ) treatment (60 mg/kg, i.v.). Rats having at least three times higher plasma glucose level than the normal were considered diabetic. Rats were treated with a single oral dose of 5 mg/kg (14)C-(methyl)-labeled (-)-deprenyl, 98 microCi/mg. Diabetic rats excreted the majority of urinary radioactivity in 8 hours, while control rats did it in 16 hours. The approximate ratio of major metabolites as determined using thin-layer chromatography did not change. In conclusion, diabetic rats excreted radiolabelled-deprenyl more rapidly compared to control animals. Increased elimination of deprenyl should be taken into account in the management of patients suffering from diabetes.",
keywords = "Deprenyl, diabetes, pharmacokinetics, urinary elimination.",
author = "Ernest Adeghate and P. S{\'o}tonyi and H. Kal{\'a}sz",
year = "2008",
month = "1",
day = "10",
doi = "10.2174/1874104500802010001",
language = "English",
volume = "2",
pages = "1--5",
journal = "Open Medicinal Chemistry Journal",
issn = "1874-1045",
publisher = "Bentham Science Publishers B.V.",

}

TY - JOUR

T1 - Chronic experimental diabetes accelerates urinary elimination of deprenyl and its metabolites

AU - Adeghate, Ernest

AU - Sótonyi, P.

AU - Kalász, H.

PY - 2008/1/10

Y1 - 2008/1/10

N2 - Many diabetic patients take several medications to treat diabetes-associated complications and other ailments. The mode of elimination of these drugs and their metabolites are poorly understood. The elimination of deprenyl, a MAO-B inhibitor, used for the treatment of the early stage of Parkinson's disease and senile dementia was investigated using thin layer chromatography.Male Wistar rats (180-200 g) were rendered diabetic by streptozotocin (STZ) treatment (60 mg/kg, i.v.). Rats having at least three times higher plasma glucose level than the normal were considered diabetic. Rats were treated with a single oral dose of 5 mg/kg (14)C-(methyl)-labeled (-)-deprenyl, 98 microCi/mg. Diabetic rats excreted the majority of urinary radioactivity in 8 hours, while control rats did it in 16 hours. The approximate ratio of major metabolites as determined using thin-layer chromatography did not change. In conclusion, diabetic rats excreted radiolabelled-deprenyl more rapidly compared to control animals. Increased elimination of deprenyl should be taken into account in the management of patients suffering from diabetes.

AB - Many diabetic patients take several medications to treat diabetes-associated complications and other ailments. The mode of elimination of these drugs and their metabolites are poorly understood. The elimination of deprenyl, a MAO-B inhibitor, used for the treatment of the early stage of Parkinson's disease and senile dementia was investigated using thin layer chromatography.Male Wistar rats (180-200 g) were rendered diabetic by streptozotocin (STZ) treatment (60 mg/kg, i.v.). Rats having at least three times higher plasma glucose level than the normal were considered diabetic. Rats were treated with a single oral dose of 5 mg/kg (14)C-(methyl)-labeled (-)-deprenyl, 98 microCi/mg. Diabetic rats excreted the majority of urinary radioactivity in 8 hours, while control rats did it in 16 hours. The approximate ratio of major metabolites as determined using thin-layer chromatography did not change. In conclusion, diabetic rats excreted radiolabelled-deprenyl more rapidly compared to control animals. Increased elimination of deprenyl should be taken into account in the management of patients suffering from diabetes.

KW - Deprenyl

KW - diabetes

KW - pharmacokinetics

KW - urinary elimination.

UR - http://www.scopus.com/inward/record.url?scp=85054434140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054434140&partnerID=8YFLogxK

U2 - 10.2174/1874104500802010001

DO - 10.2174/1874104500802010001

M3 - Article

C2 - 19662137

VL - 2

SP - 1

EP - 5

JO - Open Medicinal Chemistry Journal

JF - Open Medicinal Chemistry Journal

SN - 1874-1045

ER -